A Randomized, Crossover Study to Evaluate the Pharmacokinetics of Amantadine and Oseltamivir Administered Alone and in Combination
2007

Study on Amantadine and Oseltamivir for Influenza Treatment

Sample size: 17 publication 10 minutes Evidence: moderate

Author Information

Author(s): Morrison Dennis, Roy Sandip, Rayner Craig, Amer Ahmed, Howard Dan, Smith James R., Evans Thomas G.

Primary Institution: Bio-Kinetic Clinical Applications, Novartis Exploratory Clinical Development, F. Hoffmann-La Roche Ltd.

Hypothesis

Can the combination of amantadine and oseltamivir improve treatment outcomes for avian H5N1 infection without significant drug interactions?

Conclusion

The combination of amantadine and oseltamivir appears safe and does not significantly affect the pharmacokinetics of either drug.

Supporting Evidence

  • The study involved 17 healthy subjects who served as their own controls.
  • No significant adverse events were reported during the trial.
  • Pharmacokinetic parameters showed no clinically meaningful interactions between the two drugs.

Takeaway

This study tested two flu medicines together to see if they work well without causing problems, and they found that they do!

Methodology

A randomized, crossover, open-label trial with 17 healthy subjects receiving amantadine and oseltamivir alone and in combination over multiple treatment periods.

Potential Biases

Potential bias due to funding from pharmaceutical companies involved in the study.

Limitations

The study was small and not powered to detect significant adverse events.

Participant Demographics

17 healthy adults, aged 18 to 45, including 4 women and 13 men.

Statistical Information

P-Value

p<0.05

Confidence Interval

90% CI for AUC0-12 of amantadine: (0.89, 0.98); for oseltamivir: (0.86, 0.99)

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0001305

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication